Posts by: Alice Melão

Alice Melão

April 4, 2018

Phase 3 Trial Testing Darolutamide in Castration-resistant Prostate Cancer Expected to Conclude in September

News

A Phase 3 clinical trial evaluating darolutamide (ODM-201) as a treatment for castration-resistant prostate cancer patients at high risk for metastasis is expected to conclude in September 2018, Orion, the therapy’s maker, announced. ... Read more

March 9, 2018March 9, 2018

Tracing Copper Accumulation Is Better at Detecting Prostate Cancer Recurrence, Study Finds

News

A new imaging agent detecting copper accumulation in tumors is better at detecting early prostate cancer relapse than the tracing molecules used currently, an Italian study shows. Because the new agent ... Read more

January 31, 2018

Trial to Assess Whether Tyme Therapy or Monitoring Is Better for Prostate Cancer Patients

News

A clinical trial will assess whether Tyme Technologies’ SM-88 is a better treatment option than active surveillance for prostate cancer patients who have not had surgery, radiation, or chemotherapy. Tyme has asked an ... Read more

January 24, 2018January 24, 2018

Researchers Identify Gene Isoform Linked to Castration-resistant Prostate Cancer

News

Losing expression of a certain isoform of the HSD17B4 gene makes men more likely to get castration-resistant prostate cancer (CRPC), a lethal form of the disease that does not respond to ... Read more

January 11, 2018January 11, 2018

Profound Medical Enrolls Last Patients in Phase 2 Trial of Minimally Invasive Ablation Method

News

The pivotal Phase 2 trial evaluating TULSA-PRO system, a minimally invasive procedure that ablates prostate cancer tissue, has enrolled 87 percent of all estimated participants, Profound Medical announced. The TACT study has already ... Read more

January 3, 2018January 11, 2018

Enrollment Completed for Phase 3 Trial Evaluating 1404 Radioactive Imaging Agent

News

Progenics Pharmaceuticals has completed enrollment in the Phase 3 study assessing its PSMA-targeted imaging agent 1404 as a tool to identify prostate cancer patients with clinically significant disease. “The results of this ... Read more

January 2, 2018January 2, 2018

FDA Grants Janssen Biotech’s Apalutamide Priority Review Designation to Treat Non-metastatic CRPC

News

The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC). This ... Read more

December 8, 2017

Shorter but Higher-dose Radiation Course Cuts Risk of Prostate Cancer Returning, Study Finds

News

Delivering radiation in a shorter time frame significantly reduced the chance of prostate cancer returning in men with an intermediate-risk form of the disease, a study found. The approach failed ... Read more

December 1, 2017

Study Furthers Understanding of Low Testosterone Levels in Prostate Cancer Risk

News

Men with very low testosterone levels are less likely to develop prostate cancer, but if they do, chances are they will develop an aggressive form of the disease, according to ... Read more

November 21, 2017November 21, 2017

Consuming Certain Plants Increases Risk of a Man Developing Advanced Prostate Cancer, Study Finds

News

A diet rich in soybeans, flaxseed, green tea, strawberries and other plants doubles a man’s risk of developing an aggressive form of prostate cancer, a study indicates. Researchers found no ... Read more